Results 41 to 50 of about 9,430 (168)

Prediction of Human Serum Concentration–Time Profiles of Golimumab and Ustekinumab Using Pharmacokinetic Data From Common Marmosets With Assessment of Anti‐Drug Antibodies

Biopharmaceutics &Drug Disposition, EarlyView.
This study identified new optimal allometric scaling exponents for human PK prediction of monoclonal antibodies with linear PKs from marmoset PK data. In addition, immunogenicity in common marmosets was evaluated following the repeated dose of golimumab and ustekinumab, minimal anti‐drug antibodies were detected.
Ayaka Tajiri, Shogo Matsumoto, Nanami Furukawa, Kensuke Kagiyama, Hiroshi Ikeda, Kazumasa Fukasawa, Hiroki Takano   +6 more
wiley   +1 more source

Facilitating Expedited Drug Approval—the Past, Present, and Future of Clinical Trials for Pediatric Rheumatic Disease

Arthritis Care &Research, EarlyView.
Pamela F. Weiss, Hermine I. Brunner
wiley   +1 more source

Novel Organelle‐Based Intracellular Immunity With Mechanistic and Therapeutic Implications

Barrier Immunity, EarlyView.
A conceptual framework illustrating how PAMPs/DAMPs initiate barrier, innate, adaptive, and intracellular immune responses, with organelle‐based intracellular immunity serving as a central integrator linking metabolism, inflammatory signaling, and therapeutic interventions to restore immune homeostasis.
Keman Xu, Shih‐Yu Hung, Fatma Saaoud, Ying Shao, Yifan Lu, Juanjuan Liu, Bo Yuan, Haiyan Xiang, Hong Wang, Xiaofeng Yang   +9 more
wiley   +1 more source

Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis

Arthritis Research & Therapy, 2019
Introduction Biosimilar infliximab has the potential for appreciable cost savings compared to its reference biologic, but dose escalation is common and increases costs.
Jeffrey R. Curtis, Fenglong Xie, Jonathan Kay, Joel D Kallich   +3 more
doaj   +1 more source

Beyond Gut Modulation: A Critical Review of the Therapeutic Potential, Safety, and Clinical Prospects of Natural Polysaccharides for IBD

Food Safety and Health, EarlyView.
In this review, we critically summarized the application of natural polysaccharides (NPs) for the treatment of IBD. This approach combines, in a unique way (right), the basic structure–activity relationships of NPs from different origins (left) with their multipronged mode of action, which involves modulation of the gut microbiota and other ...
Felix Danso, A. M. Abd El‐Aty, Kwaku Amoah, Xianghong Ju   +3 more
wiley   +1 more source

Efficacy of golimumab in patients with refractory non-infectious panuveitis

Scientific Reports
This study investigated the efficacy of golimumab in the management of refractory non-infectious panuveitis. Nineteen patients (38 eyes; mean age, 31 years) were retrospectively reviewed between June 2016 and June 2022.
Usanee Tungsattayathitthan, Nattaporn Tesavibul, Pitipol Choopong, Chaipat Treeratsakulchai, Yaninsiri Ngathaweesuk, Wilawan Sanphan, Sutasinee Boonsopon   +6 more
doaj   +1 more source

Long‐term outcomes of children with ulcerative colitis after acute severe colitis: A GETAID pédiatrique multicenter study

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Acute severe colitis (ASC) is a frequent and severe complication of ulcerative colitis (UC) with a high risk of colectomy. Effects of immunosuppressants and anti–tumor necrosis factor (anti‐TNF) agents on the risk of colectomy remain debated. We wished to study the evolution of French pediatric‐onset UC patients after ASC.
Manon Cochet, Agathe Beauvais, Frank Ruemmele, Raphael Enaud, Thierry Lamireau, Rémi Duclaux‐Loras, Claire Dupont, Stéphanie Willot, Laure Bridoux‐Henno, Georges Dimitrov, Julie Lemale, Vincent Guinard‐Samuel, Valérie Bertrand, Anne Breton, Christine Martinez Vinson, Stéphanie Coopman, Delphine Ley, Bénédicte Pigneur, and the Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du tube Digestif (GETAID) pédiatrique   +18 more
wiley   +1 more source

Efficacy of Ozoralizumab vs. Golimumab for Rheumatoid Arthritis: A Systematic Review

Current Internal Medicine Research and Practice Surabaya Journal
Introduction: Rheumatoid arthritis, a systemic autoimmune disease, affects 13% of the world population. As a well-established therapy, golimumab provides a key benchmark for assessing novel biological treatments.
Nathania Elma Fithriyah, Khafiyah Hikmah Rahmadhani, Luthfiana Rofhani Susanti, Arifa Mustika, Lita Diah Rahmawati, Citrawati Dyah Kencono Wungu   +5 more
doaj   +1 more source

A case of idiopathic necrotizing scleritis with secondary glaucoma treated successfully with golimumab and Ahmed valve implantation

Indian Journal of Ophthalmology, 2019
A 52-year-old woman presented with idiopathic active scleritis not responding to oral cyclophosphamide, azathioprine, and oral steroid. Her intraocular pressure in the left eye was 45 mm of Hg in spite of using combination of brinzolamide 1% and ...
Parthopratim Dutta Majumder, Jayshree, Rathini Lilian David, Viswanath Kaushik   +3 more
doaj   +1 more source

Mesenchymal stromal cell therapy for rheumatoid arthritis: Long‐term efficacy, safety, and mechanistic insights

Rheumatology &Autoimmunity, EarlyView.
Graphical abstract summarizing the multifactorial pathogenesis of rheumatoid arthritis (RA) and the therapeutic potential of mesenchymal stromal cell (MSC) therapy. MSCs provide promising benefits through their immunomodulatory properties, low immunogenicity, ability to promote tissue repair, and multi‐lineage differentiation, presenting a potential ...
Yingjia Chen, Ruiyu Gao, Xing Guo, Genhong Yao, Xiaojun Tang, Yile E. Liu, Lingyun Sun   +6 more
wiley   +1 more source